We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+13.75%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.01B
AUM Growth
+$76.5M
(+8.2%)
Cap. Flow
+$11.5M
Cap. Flow
% of AUM
1.15%
Top 10 Holdings %
Top 10 Hldgs %
62.46%
Holding
63
New
12
Increased
4
Reduced
12
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Arbutus Biopharma
ABUS
|
+$55.6M |
| 2 |
DVAX
Dynavax Technologies
DVAX
|
+$49.8M |
| 3 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$18.8M |
| 4 |
Ascendis Pharma A/S
ASND
|
+$18.6M |
| 5 |
Omeros
OMER
|
+$17.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BLUE
bluebird bio
BLUE
|
+$31.1M |
| 2 |
RGLS
Regulus Therapeutics
RGLS
|
+$20.9M |
| 3 |
FWP
Forward Pharma A/S American Depositary Shares
FWP
|
+$20.2M |
| 4 |
Novavax
NVAX
|
+$14.7M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$13.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 70.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SGMO
1
CALL
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $94.1M | 9.34% |
6,000,000
| – | – |
|
|
ACHN
2
DELISTED
Achillion Pharmaceuticals
ACHN
| $80.9M | 8.04% |
8,207,530
+1,507,530
| +23% | +$18.8M |
|
|
DYAX
3
DELISTED
DYAX CORPORATION
DYAX
| $70.5M | 7% |
4,207,594
-738,103
| -15% | -$11.5M |
|
4
BioCryst Pharmaceuticals
BCRX
$2.42B
| $62.5M | 6.21% |
6,926,617
-123,739
| -2% | -$1.28M |
|
|
RGLS
5
DELISTED
Regulus Therapeutics
RGLS
| $60.8M | 6.04% |
29,922
-9,602
| -24% | -$20.9M |
|
|
DRNA
6
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $58.4M | 5.8% |
2,428,571
| – | – |
|
|
DVAX
7
DELISTED
Dynavax Technologies
DVAX
| $58.3M | 5.79% |
+2,600,000
| New | +$49.8M |
|
8
TG Therapeutics
TGTX
$8.19B
| $48.4M | 4.8% |
3,125,149
-225,300
| -7% | -$3.41M |
|
9
Coherus Oncology
CHRS
$217M
| $47.6M | 4.72% |
1,555,355
| – | – |
|
|
10
Arbutus Biopharma
ABUS
$847M
| $47.4M | 4.71% |
+2,714,800
| New | +$55.6M |
|
11
Xencor
XNCR
$1.45B
| $32.9M | 3.27% |
2,149,423
+750,000
| +54% | +$11.8M |
|
12
Larimar Therapeutics
LRMR
$377M
| $29M | 2.88% |
61,080
| – | – |
|
|
BLUE
13
DELISTED
bluebird bio
BLUE
| $24.2M | 2.4% |
15,469
-23,604
| -60% | -$31.1M |
|
|
BLCM
14
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $23.8M | 2.36% |
102,640
| – | – |
|
|
ZSPH
15
DELISTED
ZS PHARMA INC COMS TK (DE)
ZSPH
| $23.8M | 2.36% |
564,483
| – | – |
|
|
SGMO
16
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $19.1M | 1.9% |
1,220,209
| – | – |
|
|
17
Ascendis Pharma A/S
ASND
$16.5B
| $17.8M | 1.76% |
+1,023,652
| New | +$18.6M |
|
|
JUNO
18
DELISTED
Juno Therapeutics, Inc.
JUNO
| $17M | 1.69% |
280,000
| – | – |
|
|
19
Omeros
OMER
$845M
| $16.5M | 1.64% |
+749,000
| New | +$17.1M |
|
20
Protara Therapeutics
TARA
$214M
| $14.5M | 1.44% |
31,250
| – | – |
|
|
AGRX
21
DELISTED
Agile Therapeutics
AGRX
| $13.5M | 1.34% |
+729
| New | +$12.8M |
|
|
22
Novavax
NVAX
$1.21B
| $11.8M | 1.18% |
71,562
-90,492
| -56% | -$14.7M |
|
23
TherapeuticsMD
TXMD
$23.8M
| $10.2M | 1.01% |
33,608
-30,615
| -48% | -$7.47M |
|
|
ARRY
24
DELISTED
Array Biopharma Inc
ARRY
| $10M | 0.99% |
+1,357,584
| New | +$9.66M |
|
|
CNCE
25
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $10M | 0.99% |
+660,000
| New | +$9.21M |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q1 2015 Portfolio in Review
As of Q1 2015, RA Capital Management held 63 positions worth $1.01B, up 8.2% from $930M the previous quarter. Its ten largest holdings account for 62% of the portfolio.
RA Capital Management's Q1 2015 filing shows 12 new, 4 increased, 12 reduced and 6 closed positions. Its largest new stake was Arbutus Biopharma: 2,714,800 shares worth $47.4M. The largest sale was bluebird bio, an estimated $31.1M.
By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 65% a quarter earlier.
- RA Capital Management's largest Q1 2015 buy was Arbutus Biopharma: 2,714,800 shares worth $47.4M.
- RA Capital Management added most to Achillion Pharmaceuticals in Q1 2015, an estimated $18.8M increase.
- RA Capital Management's biggest Q1 2015 reduction was bluebird bio, cutting an estimated $31.1M.
- RA Capital Management fully exited Forward Pharma A/S American Depositary Shares in Q1 2015, selling an estimated $20.2M.
- RA Capital Management's ten largest holdings make up 62% of its $1.01B portfolio in Q1 2015.
- RA Capital Management opened 12 new positions and closed 6 in Q1 2015.
- RA Capital Management's portfolio value rose 8.2% quarter-over-quarter to $1.01B.
Based on RA Capital Management's 13F filing for Q1 2015, filed 15 May 2015.